Thorne HealthTech, Inc.

NasdaqGS:THRN 株式レポート

時価総額：US$550.6m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Thorne HealthTech 将来の成長

Future 基準チェック /46

Thorne HealthTechは、57.2%と19.8%でそれぞれ年率57.2%で利益と収益が成長すると予測される一方、EPSはgrowで56.6%年率。

主要情報

57.2%

収益成長率

56.62%

EPS成長率

Personal Products 収益成長33.1%
収益成長率19.8%
将来の株主資本利益率n/a
アナリストカバレッジ

Low

最終更新日16 Oct 2023

今後の成長に関する最新情報

分析記事 • Aug 12

Results: Thorne HealthTech, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts

Thorne HealthTech, Inc. ( NASDAQ:THRN ) defied analyst predictions to release its second-quarter results, which were...

Recent updates

分析記事 • Aug 12

Results: Thorne HealthTech, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts

Thorne HealthTech, Inc. ( NASDAQ:THRN ) defied analyst predictions to release its second-quarter results, which were...
分析記事 • Jun 07

Thorne HealthTech, Inc. (NASDAQ:THRN) Not Flying Under The Radar

With a price-to-earnings (or "P/E") ratio of 25.5x Thorne HealthTech, Inc. ( NASDAQ:THRN ) may be sending very bearish...
分析記事 • Dec 17

Investors Will Want Thorne HealthTech's (NASDAQ:THRN) Growth In ROCE To Persist

To find a multi-bagger stock, what are the underlying trends we should look for in a business? Firstly, we'd want to...
Seeking Alpha • Sep 09

Thorne HealthTech Grows But Faces Macro Headwinds

Summary Thorne HealthTech went public in September 2021, raising approximately $70 million in a U.S. IPO. The company designs and sells wellness and nutraceutical products worldwide. THRN has produced revenue growth but faces inflationary pressures, the loss of a significant distributor in Europe and the stock may be fully valued here. I'm on Hold for THRN for the near term. A Quick Take On Thorne HealthTech Thorne HealthTech, Inc. (THRN) went public in September 2021, raising approximately $70 million in gross proceeds from an IPO that priced at $10.00 per share. The firm designs and sells wellness and nutraceutical products under its brands Thorne and Onegevity. Given the risks of continued inflationary pressures and a macroeconomic slowdown combined with a potentially fully valued stock at its current price of around $5.00 per share, I'm on Hold for THRN in the near term. Thorne HealthTech Overview New York, NY-based Thorne was founded to develop premium wellness products for consumers utilizing its Onegevity platform to discover and develop new products. The firm sells products directly and also has a product subscription program Management is headed by Chief Executive Officer Paul Jacobson, who has been with the firm since 2010 when he acquired Thorne Research and was previously co-founder of Onegevity Health, which was acquired by Thorne. THRN sells its products through a direct to consumer channel [DTC] as well as through online ecommerce sites such as Amazon, distributors and through connected health professionals. The company also gathers personalized testing data and has plans to use this information for additional services to practitioners. Thorne HealthTech's Market & Competition According to a 2021 market research report by Grand View Research, the global market for dietary supplements was an estimated $140.3 billion in 2020 and is forecast to reach $271 billion by 2028. This represents a forecast CAGR of 8.6% from 2021 to 2028. The main drivers for this expected growth are a growing consumer awareness of personal health and wellness products as well as increased R&D from product makers. Also, below is a chart showing the historical and projected future market size by ingredient for dietary supplements in the U.S.: U.S. Dietary Supplements Market (Grand View Research) Major competitive or other industry participants include: Nestle Health Science Metagenics Hims 23and Me Livongo Schrodinger SEMA4 Numerous other nutritional supplement companies Thorne HealthTech's Recent Financial Performance Total revenue by quarter has grown according to the following chart: 9 Quarter Total Revenue (Seeking Alpha) Gross profit by quarter has followed approximately the same trajectory as that of total revenue: 9 Quarter Gross Profit (Seeking Alpha) Selling, G&A expenses as a percentage of total revenue by quarter rose substantially in the most recent quarter: 9 Quarter Selling, G&A % Of Revenue (Seeking Alpha) Operating income by quarter has turned negative in Q2 2022: 9 Quarter Operating Income (Seeking Alpha) Earnings per share (Diluted) have turned into negative territory in Q2 2022: 9 Quarter Earnings Per Share (Seeking Alpha) (All data in above charts is GAAP) Since its IPO, THRN's stock price has fallen 38.4% vs. the U.S. S&P 500 index' drop of around 9.9%, as the chart below indicates: Stock Price Since IPO (Seeking Alpha) Valuation And Other Metrics For Thorne HealthTech Below is a table of relevant capitalization and valuation figures for the company: Measure [TTM] Amount Enterprise Value / Sales 1.31 Revenue Growth Rate 28.5% Net Income Margin 0.97 GAAP EBITDA % 1.8% Market Capitalization $267,930,000 Enterprise Value $272,780,000 Operating Cash Flow $1,190,000 Earnings Per Share (Fully Diluted) $0.04 (Source - Seeking Alpha) Below is an estimated DCF (Discounted Cash Flow) analysis of the firm's projected growth and earnings: Discounted Cash Flow - Thorne (GuruFocus) Assuming generous DCF parameters, the firm's shares would be valued at approximately $5.13 versus the current price of $5.01, indicating they are potentially currently fully valued, with the given earnings, growth and discount rate assumptions of the DCF. As a reference, a relevant partial public comparable would be larger firm Glanbia plc (GLAPF, GLAPY); shown below is a comparison of their primary valuation metrics: Metric Glanbia plc Thorne HealthTech Variance Enterprise Value / Sales 0.79 1.31 65.8% Revenue Growth Rate 23.7% 28.5% 20.3% Net Income Margin 5.4% 0.97 1689.7% Operating Cash Flow $104,990,000 $1,190,000 -98.9% (Source - Seeking Alpha) A full comparison of the two companies' performance metrics may be viewed here. Commentary On Thorne HealthTech In its last earnings call (Source - Seeking Alpha), covering Q2 2022's results, management highlighted improvements in its sales mix and the effect of increased prices and scale growth as offsets to inflationary pressures on its cost of sales. Notably, the firm's Pro and B2B sales channels produced strong growth year-over-year, excluding the loss of a distributor related to the conflict in Ukraine, which it estimates reduced Q2 revenue by "as much as $6.9 million."
Seeking Alpha • Aug 23

Thorne HealthTech's blood collection device OneDraw gets clearance in Japan

Thorne HealthTech (NASDAQ:THRN) said its blood collection device OneDraw was certified in Japan as a medical device after being cleared by the Pharmaceutical and Medical Devices Agency (PMDA). "We appreciate the help from our partners in Japan because we believe this will create many additional opportunities to expand our relationships globally, while we continue to move forward on a similar regulatory pathway in the United States," said Thorne CEO Paul Jacobson. The company noted that OneDraw is already approved by the FDA as a class 2 medical device, and it has a European Conformity mark for supervised use by health-care professionals to collect blood samples to measure HbA1c for monitoring the long-term control of blood sugar (glucose) in diabetic individuals.
Seeking Alpha • Aug 09

Thorne HealthTech swings to Q2 Non-GAAP loss per share, revenue down Y/Y, FY22 guidance revised

Thorne HealthTech press release (NASDAQ:THRN): Q2 Non-GAAP EPS of -$0.05 (vs. $0.22 Y/Y). Revenue of $56.1M (+30.8% Y/Y). FY22 guidance revised to net sales of $235M to $242M (vs. consensus of $247.13M) and EPS of of $0.36 to $0.39 (vs. consensus of $0.34). Shares -1.47% AH.
Seeking Alpha • Jun 05

Thorne HealthTech: Poised To Outperform Other Nutraceutical Companies

Nutraceutical companies will perform well during the next decade, even during a recession. DIY health trends are on the rise. Thorne HealthTech is well-positioned to benefit from these trends.
分析記事 • Mar 23

Shareholders Can Be Confident That Thorne HealthTech's (NASDAQ:THRN) Earnings Are High Quality

Thorne HealthTech, Inc.'s ( NASDAQ:THRN ) strong earnings report was rewarded with a positive stock price move. We have...
Seeking Alpha • Jan 11

Thorne HealthTech: Good Potential At A Low Price

The market oversold Thorne shares. The company is growing at double-digit rates. It has strong positioning and enormous market potential. If marketing efficiency remains the same in the coming years, revenue will grow exponentially. This scenario is highly likely because the indicator is increasing. Despite the stage of aggressive growth, Thorne is already a profitable company. We expect the company to continue growing and improve profitability. The company is trading at a significant discount to its fair market value. PEG ratio is less than 1.

業績と収益の成長予測

NasdaqGS:THRN - アナリストの将来予測と過去の財務データ ( )USD Millions
日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数
12/31/20254186865722
12/31/20243633461683
12/31/20232881617472
6/30/202325820-1522N/A
3/31/202324010-254N/A
12/31/202222916-135N/A
9/30/20222166-14-6N/A
6/30/20222063-51N/A
3/31/20221949-11-4N/A
12/31/2021184449N/A
9/30/2021172-1812N/A
6/30/2021162-1912N/A
3/31/2021150-32023N/A
12/31/2020138-31517N/A
12/31/2019103-22-11-8N/A

アナリストによる今後の成長予測

収入対貯蓄率: THRNの予測収益成長率 (年間57.2% ) は 貯蓄率 ( 2.2% ) を上回っています。

収益対市場: THRNの収益 ( 57.2% ) はUS市場 ( 16.8% ) よりも速いペースで成長すると予測されています。

高成長収益: THRNの収益は今後 3 年間で 大幅に 増加すると予想されています。

収益対市場: THRNの収益 ( 19.8% ) US市場 ( 11.7% ) よりも速いペースで成長すると予測されています。

高い収益成長: THRNの収益 ( 19.8% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: THRNの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

成長企業の発掘

7D

1Y

7D

1Y

7D

1Y

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2023/10/18 07:13
終値2023/10/13 00:00
収益2023/06/30
年間収益2022/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Thorne HealthTech, Inc. 3 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。5

アナリスト機関
Bryan SpillaneBofA Global Research
Susan AndersonCanaccord Genuity
Elizabeth AndersonEvercore ISI